Abstracts tagged "Health care cost"

Abstract Number: 1054 • 2017 ACR/ARHP Annual Meeting
Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis
Nina Mars^1,2, Anne M Kerola^2,3, Markku J Kauppi^4,5, Matti Pirinen¹, Outi Elonheimo⁶ and Tuulikki Sokka-Isler⁷, ¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Utilization patterns in rheumatoid arthritis (RA) are complex. For targeted interventions, patients with special healthcare needs should be recognized. Our aim was to explore…
Abstract Number: 1561 • 2017 ACR/ARHP Annual Meeting
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Biologic-NaïVe Psoriatic Arthritis
Vibeke Strand¹, M. Elaine Husni², Rakesh Singh³, Keith Betts⁴, Yan Song⁵, Jenny Griffith³ and Arijit Ganguli³, ¹Stanford University, Palo Alto, CA, ²Cleveland Clinic, Cleveland, OH, ³AbbVie Inc., North Chicago, IL, ⁴Analysis Group, Inc., Los Angeles, CA, ⁵Analysis Group, Inc., Boston, MA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory condition characterized by peripheral arthritis and psoriatic skin lesions requiring therapies that control both skin and joint symptoms.…
Abstract Number: 2260 • 2017 ACR/ARHP Annual Meeting
Communication Strategies Are Highly Important to Avoid Nocebo Effect When Performing Non-Medical Switch from Originator Product to Biosimilar Product: Danish Results from Applying the Parker Model a Qualitative 3-Step Research Model
Tanja Schjødt Jørgensen¹, Marie Skougaard¹, Hans Christian Asmussen^2,3, Anne Lee⁴, Peter C. Taylor⁵, Henrik Gudbergsen¹ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ²NATiON, Copenhagen, Denmark, ³Communication IKH, Roskilde University, Roskilde, Denmark, ⁴University of Southern Denmark, Odense, Denmark, ⁵University of Oxford Botnar Research Centre, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: Introducing a non-medical switch from originator to a biosimilar product in the management of chronic arthritis, i.e. switching patients in remission or low disease…
Abstract Number: 2812 • 2017 ACR/ARHP Annual Meeting
Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis
Christopher F Bell¹, Julie Priest^2,3, Marni Stott-Miller⁴, Hong Kan⁵, Justyna Amelio⁶, Xue Song⁷, Brendan Limone⁷, Virginia Noxon⁷ and Karen H. Costenbader⁸, ¹GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, ³US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, ⁴GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, ⁵Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁶GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, ⁷Truven Health Analytics, an IBM company, Ann Arbor, MI, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. There is…
Abstract Number: 2831 • 2017 ACR/ARHP Annual Meeting
Real-World Experience with Tofacitinib Versus Adalimumab and Etanercept in Biologic-Naive Patients with RA Previously Treated with Methotrexate: Data from a US Administrative Healthcare Insurance Claims Database
Tim Smith¹, James Harnett¹, David Gruben², Connie Chen¹, Ekta Agarwal¹ and John Woolcott³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib access has been restricted by many US payers to use after…
Abstract Number: 2836 • 2017 ACR/ARHP Annual Meeting
The Additional Economic Burden of Depression Among Adults with Rheumatoid Arthritis in the United States
Nan Li and Steven Peterson, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Depression is significantly more prevalent in patients with rheumatoid arthritis (RA) compared with the general population.1 It has a significant effect on RA patients,…
Abstract Number: 2895 • 2017 ACR/ARHP Annual Meeting
Predictors of Hospitalization, Length of Stay and Costs of Care Among Children with Juvenile Dermatomyositis in the United States
Michael C. Kwa¹, Jonathan I. Silverberg² and Kaveh Ardalan^3,4, ¹Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disease that causes significant morbidity and quality of life impairment. Little is known about JDM inpatient burden…
Abstract Number: 1248 • 2016 ACR/ARHP Annual Meeting
Access to Care: The Patient Perspective from the 2015 ACR/ARHP Workforce Study
Seetha Monrad¹, Lisa Imundo², Daniel Battafarano³ and Marcia Ditmyer⁴, ¹Internal Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ²Pediatrics, Columbia University, New York, NY, ³Medicine, San Antonio Military Medical Center, San Antonio, TX, ⁴University of Nevada, Las Vegas, NV
Background/Purpose: The 2015 Workforce Study (WFS) sought to expand our current understanding of the rheumatology workforce utilizing an integrated, patient-centered approach to workforce modeling. Primary…
Abstract Number: 2234 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
Sergio Schwartzman¹, Yunfeng Li², Huanxue Zhou³, Vivian Herrera² and Jacqueline B. Palmer², ¹Hospital for Special Surgery, New York, NY, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³KMK Consulting Inc, East Hanover, NJ
Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2 Affiliations: 1Hospital for Special Surgery, New York, NY, US; 2Novartis Pharmaceuticals Corporation, East Hanover,…
Abstract Number: 3152 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA): Premature Use of Biologics Accelerating in United States (US)
James R. O'Dell¹, Stanley B. Cohen², J Carter Thorne³ and Ted R Mikuls⁴, ¹Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The treatment of RA has changed dramatically in the past several decades with the advent of a large number of new biologic agents as…
Abstract Number: 104 • 2016 ACR/ARHP Annual Meeting
Incremental Direct Expenditures Due to Osteoarthritis: A Nationally Representative Study Using Medical Expenditure Panel Survey Data
Jyothi Menon, Purdue University, West Lafayette, IN
Background/Purpose: Osteoarthritis is characterized by symptoms related to abnormalities in joints, subchondral bones and periarticular structures. In the United States, it was estimated that twenty-seven…
Abstract Number: 111 • 2016 ACR/ARHP Annual Meeting
Influences of Osteoarthritis Pain, Comorbid Insomnia, and Depression on Health Care Use in Older Adults with Osteoarthritis
Minhui Liu¹, Susan M. McCurry¹, Michael V. Vitiello², Basia Belza¹ and Michael Von Korff³, ¹University of Washington School of Nursing, Seattle, WA, ²Psychiatry and Behavioral Sciences, Biobehavioral Nursing and Health Systems, University of Washington School of Medicine, Seattle, WA, ³Group Health Research Institute, Seattle, WA
Background/Purpose: Osteoarthritis (OA), the most common type of arthritis, is prevalent and costly. Pain is the principal reason patients with OA seek treatment. Older adults…
Abstract Number: 1223 • 2016 ACR/ARHP Annual Meeting
The Cost of Confronting Osteoporosis:Cost Study of a Fracture Liaison Service
Gabor Major^1,2, Rod Ling^3,4, Andrew Searles^3,4, Fiona Niddrie⁵, Ayano Nakayama⁶, Elizabeth Holliday^4,7, John Attia^4,7 and Nikolai Bogduk^4,6, ¹Rheumatology, Bone and Joint Institute, John Hunter Hospital NSW Australia, Newcastle, Australia, ²Medicine, University of Newcastle, Newcastle, Australia, ³Health Economics, Hunter Medical Research Institute, Newcastle, Australia, ⁴University of Newcastle, Newcastle, Australia, ⁵Rheumatology, Bone and Joint Institute,John Hunter Hospital, Newcatle, Australia, ⁶Rheumatology, Bone and Joint Institute,John Hunter Hospital, Newcastle, Australia, ⁷Hunter Medical Research Institute, Newcastle, Australia
Background/Purpose: Services that actively seek out and identify patients with fractures following a minimal trauma injury have been promoted as the most effective means of…
Abstract Number: 1231 • 2016 ACR/ARHP Annual Meeting
Impact of Comorbidity on Health-Related Quality of Life and Healthcare Expenditure in Patients with Rheumatoid Arthritis
Eric Nyarko¹ and J An², ¹College of Pharmacy, Western University of Health Sciences, Pomona, CA, ²Western University of Health Sciences, Pomona, CA
Background/Purpose: Rheumatoid Arthritis (RA) is known to be associated with an increased risk of comorbidity, premature mortality, and disability. We investigated the effect of comorbidity…
Abstract Number: 1236 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs
Karina Raimundo¹, Amanda Farr², Ashley Cole³ and Jeffrey J. Swigris⁴, ¹Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Truven Health Analytics, Bethesda, MD, ⁴Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO
Background/Purpose: Interstitial lung disease (ILD) is commonly associated with rheumatoid arthritis (RA) and can have significant morbidity and mortality. The objective was to calculate the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.